LNKS vs TCRT: Contrasting Two Micro-Cap Stocks in Manufacturing and Biotech
Key Takeaways
- LNKS (Linkers Industries) is a Malaysia-based manufacturer of wire and cable harnesses, while TCRT (Alaunos Therapeutics) is a clinical-stage biotechnology company.
- The two companies operate in unrelated sectors—industrial manufacturing versus oncology and cardiopulmonary drug development—making this a study in contrasting risk profiles.
- LNKS recently executed a 1-for-250 reverse share split and raised roughly $16 million in gross proceeds through the exercise of Series B warrants.
- TCRT completed its acquisition of Velaris Therapeutics and secured new financing, but reports minimal cash, near-zero revenue, and ongoing net losses.
- Both are small-cap, thinly traded securities with histories of share consolidation and elevated price volatility.
Introduction
Comparing two micro-cap stocks from entirely different industries can reveal how market positioning, capital structure, and catalysts shape relative performance. LNKS, a Malaysian wire-harness manufacturer, and TCRT, a clinical-stage biopharmaceutical developer, present sharply different business models and risk dynamics. This stock comparison is relevant to traders evaluating momentum and volatility, as well as investors assessing fundamental quality, financing needs, and long-term viability. Both names have recently undergone corporate actions that influenced their share prices, making a side-by-side review of their recent market behavior and positioning timely. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.
LNKS Overview and Recent Performance
Linkers Industries Limited is a manufacturer and supplier of customized wire and cable harnesses with more than 20 years of experience and operations in Malaysia. The company serves global brand-name manufacturers and original equipment manufacturers (OEMs) across home appliances, industrial products, and automotive applications, primarily in the Asia-Pacific region.
In recent market activity, LNKS has been shaped by corporate capital events rather than purely operational news. The company announced a 1-for-250 reverse share split of its Class A and Class B ordinary shares, a consolidation intended to address its low share price. Around the same period, it disclosed that all Series B warrants tied to its March 2026 public offering had been fully exercised, generating approximately $16 million in gross proceeds. These actions have contributed to wide daily percentage swings, and the stock has traded in a notably broad range over the past year. The underlying business remains a niche industrial supplier, with its market valuation influenced heavily by limited float and capital-raising activity.
TCRT Overview and Recent Performance
Alaunos Therapeutics, Inc. is a biotechnology company historically focused on adoptive T-cell receptor (TCR-T) cell therapies for solid tumors, with additional preclinical programs in obesity. More recently, the company has pivoted toward specialty biopharma through the acquisition of Velaris Therapeutics, a private developer of therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, backed by institutional healthcare investors.
Recent performance for TCRT has reflected both restructuring and persistent financial pressure. The stock is down roughly 70% over the trailing 52 weeks and trades well below its 50-day and 200-day moving averages. The company reports very limited cash (about $124,000), essentially no meaningful revenue, and trailing twelve-month net losses of roughly $4.1 million. These figures, combined with a market capitalization of only a few million dollars and a prior 1-for-10 reverse split, highlight the dilution and funding risks that characterize the name. Sentiment has been sensitive to financing announcements, listing-compliance concerns, and pipeline updates. From what I see, the financing history adds another layer to watch closely.
Head-to-Head Comparison
The most fundamental contrast between these two stocks is their business model. LNKS operates a tangible, revenue-generating manufacturing business with established OEM relationships, whereas TCRT is a development-stage biotech whose value depends largely on future clinical milestones and continued capital infusions.
On growth drivers, LNKS's trajectory is tied to industrial and automotive demand in Asia-Pacific plus its ability to deploy newly raised capital, while TCRT's outlook rests on its acquired Velaris pipeline and the successful advancement of its programs. On risk factors, LNKS faces a concentrated customer base, thin liquidity, and a heavily consolidated share structure; TCRT confronts clinical, regulatory, and financing risk, underscored by its minimal cash balance and recurring losses.
In terms of sector exposure, LNKS offers cyclical manufacturing exposure, whereas TCRT provides speculative, event-driven healthcare exposure. Recent momentum has been headline-driven for both names—corporate actions for LNKS and restructuring announcements for TCRT—but neither has yet demonstrated durable, fundamental-backed trend consistency. I’m watching this closely as the volatility patterns evolve.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and the quality of catalysts, Tickeron's AI would likely lean toward LNKS over TCRT in the current environment. LNKS's operational revenue base and recent capital infusion provide a comparatively more stable footing, whereas TCRT's minimal cash, near-zero revenue, and heavy reliance on dilution present a less favorable risk profile. That said, this is a probabilistic assessment rather than a definitive prediction: TCRT's biotech catalysts can produce sharp moves, and both stocks carry elevated volatility. Any relative advantage would depend on sustained trend signals and improving fundamentals rather than short-term price swings.
Using AI Trading Bots in My Research
Tickeron operates hundreds of AI Trading Bots that actively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of target securities. In my own process, I find the curated selection helpful for spotting approaches that align with shifting market conditions. Exploring these tools has become a regular part of how I evaluate signals across volatile names like these.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
TCRT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 18, 2026
TCRT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 46 cases where TCRT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TCRT's RSI Indicator exited the oversold zone, 35 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 75 cases where TCRT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on TCRT as a result. In 53 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for TCRT just turned positive on October 12, 2026. Looking at past instances where TCRT's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Following a +34.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRT advanced for three days, in 177 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TCRT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.975) is normal, around the industry mean (26.823). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. TCRT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a cancer treatment company
Industry Biotechnology
Advertisement